223 related articles for article (PubMed ID: 31046673)
21. Proteinase 3 activity in sputum from subjects with alpha-1-antitrypsin deficiency and COPD.
Sinden NJ; Stockley RA
Eur Respir J; 2013 May; 41(5):1042-50. PubMed ID: 22936713
[TBL] [Abstract][Full Text] [Related]
22. Endocan Serum Levels in Patients with Non-Alcoholic Fatty Liver Disease with or without Type 2 Diabetes Mellitus: A Pilot Study.
Dallio M; Masarone M; Caprio GG; Di Sarno R; Tuccillo C; Sasso FC; Persico M; Loguercio C; Federico A
J Gastrointestin Liver Dis; 2017 Sep; 26(3):261-268. PubMed ID: 28922438
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and pharmacological characterization of 2-aminobenzaldehyde oxime analogs as dual inhibitors of neutrophil elastase and proteinase 3.
Hwang TL; Wang WH; Wang TY; Yu HP; Hsieh PW
Bioorg Med Chem; 2015 Mar; 23(5):1123-34. PubMed ID: 25650311
[TBL] [Abstract][Full Text] [Related]
24. Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes.
Lomonaco R; Bril F; Portillo-Sanchez P; Ortiz-Lopez C; Orsak B; Biernacki D; Lo M; Suman A; Weber MH; Cusi K
Diabetes Care; 2016 Apr; 39(4):632-8. PubMed ID: 26861926
[TBL] [Abstract][Full Text] [Related]
25. Neutrophils and neutrophil serine proteases are increased in the spleens of estrogen-treated C57BL/6 mice and several strains of spontaneous lupus-prone mice.
Dai R; Cowan C; Heid B; Khan D; Liang Z; Pham CT; Ahmed SA
PLoS One; 2017; 12(2):e0172105. PubMed ID: 28192517
[TBL] [Abstract][Full Text] [Related]
26. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.
Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Hultcrantz R; Kechagias S
J Hepatol; 2017 Dec; 67(6):1265-1273. PubMed ID: 28803953
[TBL] [Abstract][Full Text] [Related]
27. Proteinase 3 and neutrophil elastase enhance inflammation in mice by inactivating antiinflammatory progranulin.
Kessenbrock K; Fröhlich L; Sixt M; Lämmermann T; Pfister H; Bateman A; Belaaouaj A; Ring J; Ollert M; Fässler R; Jenne DE
J Clin Invest; 2008 Jul; 118(7):2438-47. PubMed ID: 18568075
[TBL] [Abstract][Full Text] [Related]
28. Serum uric acid and non-alcoholic fatty liver disease in non-obesity Chinese adults.
Zheng X; Gong L; Luo R; Chen H; Peng B; Ren W; Wang Y
Lipids Health Dis; 2017 Oct; 16(1):202. PubMed ID: 29037239
[TBL] [Abstract][Full Text] [Related]
29. Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance.
Gaggini M; Carli F; Rosso C; Buzzigoli E; Marietti M; Della Latta V; Ciociaro D; Abate ML; Gambino R; Cassader M; Bugianesi E; Gastaldelli A
Hepatology; 2018 Jan; 67(1):145-158. PubMed ID: 28802074
[TBL] [Abstract][Full Text] [Related]
30. Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience.
Yılmaz Y; Kanı HT; Demirtaş CÖ; Kaya E; Sapmaz AF; Qutranji L; Alkayyali T; Batun KD; Batman M; Toy B; Çiftaslan A
Turk J Gastroenterol; 2019 Oct; 30(10):892-898. PubMed ID: 31258138
[TBL] [Abstract][Full Text] [Related]
31. Lean non-alcoholic fatty liver disease and associated metabolic disturbance: A Saudi Arabian cross-sectional study.
Khayyat YM
Physiol Rep; 2021 Jul; 9(14):e14949. PubMed ID: 34278728
[TBL] [Abstract][Full Text] [Related]
32. Lean non-alcoholic fatty liver disease and risk of incident diabetes in a euglycaemic population undergoing health check-ups: A cohort study.
Wei L; Cheng X; Luo Y; Yang R; Lei Z; Jiang H; Chen L
Diabetes Metab; 2021 May; 47(3):101200. PubMed ID: 33075504
[TBL] [Abstract][Full Text] [Related]
33. Characterization of lean patients with nonalcoholic fatty liver disease: potential role of high hemoglobin levels.
Akyuz U; Yesil A; Yilmaz Y
Scand J Gastroenterol; 2015 Mar; 50(3):341-6. PubMed ID: 25540973
[TBL] [Abstract][Full Text] [Related]
34. Using a Caesalpinia echinata Lam. protease inhibitor as a tool for studying the roles of neutrophil elastase, cathepsin G and proteinase 3 in pulmonary edema.
Cruz-Silva I; Neuhof C; Gozzo AJ; Nunes VA; Hirata IY; Sampaio MU; Figueiredo-Ribeiro Rde C; Neuhof H; Araújo Mda S
Phytochemistry; 2013 Dec; 96():235-43. PubMed ID: 24140156
[TBL] [Abstract][Full Text] [Related]
35. Family history and obesity in youth, their effect on acylcarnitine/aminoacids metabolomics and non-alcoholic fatty liver disease (NAFLD). Structural equation modeling approach.
Romero-Ibarguengoitia ME; Vadillo-Ortega F; Caballero AE; Ibarra-González I; Herrera-Rosas A; Serratos-Canales MF; León-Hernández M; González-Chávez A; Mummidi S; Duggirala R; López-Alvarenga JC
PLoS One; 2018; 13(2):e0193138. PubMed ID: 29466466
[TBL] [Abstract][Full Text] [Related]
36. Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease.
Ozturk O; Colak Y; Senates E; Yilmaz Y; Ulasoglu C; Doganay L; Ozkanli S; Oltulu YM; Coskunpinar E; Tuncer I
World J Gastroenterol; 2015 Jul; 21(26):8096-102. PubMed ID: 26185381
[TBL] [Abstract][Full Text] [Related]
37. Pro-Inflammatory Cytokines but Not Endotoxin-Related Parameters Associate with Disease Severity in Patients with NAFLD.
du Plessis J; Korf H; van Pelt J; Windmolders P; Vander Elst I; Verrijken A; Hubens G; Van Gaal L; Cassiman D; Nevens F; Francque S; van der Merwe S
PLoS One; 2016; 11(12):e0166048. PubMed ID: 27992443
[TBL] [Abstract][Full Text] [Related]
38. Clinical and metabolic characterization of obese subjects without non-alcoholic fatty liver: A targeted metabolomics approach.
Feldman A; Eder SK; Felder TK; Paulweber B; Zandanell S; Stechemesser L; Schranz M; Strebinger G; Huber-Schönauer U; Niederseer D; Patsch W; Weghuber D; Tevini J; Datz C; Aigner E
Diabetes Metab; 2019 Apr; 45(2):132-139. PubMed ID: 30266576
[TBL] [Abstract][Full Text] [Related]
39. Increased Circulating Levels of Alpha-Ketoglutarate in Morbidly Obese Women with Non-Alcoholic Fatty Liver Disease.
Aragonès G; Auguet T; Berlanga A; Guiu-Jurado E; Martinez S; Armengol S; Sabench F; Ras R; Hernandez M; Aguilar C; Colom J; Sirvent JJ; Del Castillo D; Richart C
PLoS One; 2016; 11(4):e0154601. PubMed ID: 27123846
[TBL] [Abstract][Full Text] [Related]
40. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.
Estes C; Anstee QM; Arias-Loste MT; Bantel H; Bellentani S; Caballeria J; Colombo M; Craxi A; Crespo J; Day CP; Eguchi Y; Geier A; Kondili LA; Kroy DC; Lazarus JV; Loomba R; Manns MP; Marchesini G; Nakajima A; Negro F; Petta S; Ratziu V; Romero-Gomez M; Sanyal A; Schattenberg JM; Tacke F; Tanaka J; Trautwein C; Wei L; Zeuzem S; Razavi H
J Hepatol; 2018 Oct; 69(4):896-904. PubMed ID: 29886156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
